Compare Repligen Corporation Common Stock (RGEN) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs ProShares UltraPro QQQ ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while ProShares UltraPro QQQ ETF trades at $71.53 (market cap $38.26B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 3.4× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and ProShares UltraPro QQQ ETF for 25 Days on average.
| RGEN | TQQQ | |
|---|---|---|
Market Cap | $11.14B | $38.26B |
Volume | 1,259,263 | 38,965,303 |
Sector | Health | Leveraged / Inverse |
52-Week High | $194.57 | $87.22 |
52-Week Low | $102.87 | $37.89 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TQQQ trades at $78.81, down 1.0% on the day, with a bullish technical signal from moving averages but neutral oscillators. The leveraged ETF faces mixed sentiment with recent articles highlighting both strong performance during the AI boom and concerns about hidden costs and volatility decay. Support levels are established at $77-$79, with resistance at $81-$82.
The outlook remains volatile with 3x leverage amplifying both gains and losses. Key risks include expense ratios beyond the stated 0.82% and market volatility amplification. Institutional activity shows mixed positioning, with some firms reducing stakes while others add exposure to tech and AI themes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
